Business

Biotech

Sarepta sells international rights to Duchenne gene therapy to Roche

By Adam Feuerstein

Biotech

Ring Therapeutics is developing a new way to deliver gene therapy

By Jonathan Saltzman — Boston Globe

Business

The FTC moves to block DNA sequencer Illumina’s acquisition of PacBio, calling company a ‘monopolist’

By Matthew Herper

Biotech

Startup targeting DNA repeats in Huntington’s and other diseases debuts with $59 million

By Jonathan Saltzman — Boston Globe

Business

Purdue, maker of OxyContin, quietly splits ways with PhRMA as it pulls back from lobbying

By Nicholas Florko

Biotech

Bankrupt uBiome preliminarily sells patents for 1% of the poop-testing startup’s original valuation

By Erin Brodwin

Biotech

In tight Massachusetts job market, it’s relo for biotech and remote for tech hires

By Scott Kirsner — Boston Globe

Biotech

Bristol-Myers CMO on cell therapies: ‘This is the best time to be in drug development’

By Adam Feuerstein

Biotech

Vindicated. New J&J CAR-T myeloma data confirm strong efficacy, ease doubts raised by Chinese version

By Adam Feuerstein

Biotech

New data show Bluebird, Bristol CAR-T drug could be pioneering myeloma therapy. Competitors may be close behind

By Adam Feuerstein and Damian Garde

Business

How difficult is a $1 billion health-tech fraud? A new indictment makes it sound easy

By Matthew Herper

Biotech

Global Blood secures FDA approval for new pill to treat sickle cell disease

By Adam Feuerstein

Business

Facing bottlenecks in manufacturing cell therapies, Boston leaders plan to build their own

By Sharon Begley

Biotech

With $9.7 billion acquisition, Novartis bets that heart drugs are coming back

By Matthew Herper

Business

Patient charity settles allegations it helped MS drug makers pay kickbacks

By Elizabeth Cooney

Biotech

Roche buying Promedior for $390 million to develop drugs for fibrotic disease

By Jonathan Saltzman — Boston Globe

Biotech

An FDA panel backed Amarin’s fish oil drug. Here’s a detailed breakdown of the debate

By Adam Feuerstein and Matthew Herper

Politics

Mass. governor — and one-time insurance executive — eyes a legacy-defining revamp of state’s health care

By Priyanka Dayal McCluskey — Boston Globe and Matt Stout — Boston Globe

Biotech

FDA documents point to a broadened approval for Amarin’s heart pill Vascepa

By Matthew Herper and Adam Feuerstein

Biotech

Sarepta Therapeutics CEO playing nice with FDA over rejection of Duchenne drug

By Adam Feuerstein

Biotech

Startup Arkuda targets rapidly advancing, rare form of dementia

By Jonathan Saltzman — Boston Globe

Pharmalot

If Trump were to place tariffs on Swiss drugs, U.S. patients are most likely to get hurt

By Ed Silverman

Health

A new Alzheimer’s therapy is approved in China, delivering a surprise for the field but also questions

By Andrew Joseph

Business

Amgen acquires stake in BeiGene to expand cancer drug business to China

By Adam Feuerstein

Biotech

Novartis’ Zolgensma gene therapy study halted by FDA on animal safety concerns

By Adam Feuerstein

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Blueprint gains approval for its first drug, a treatment for a rare gastrointestinal cancer

At 2020 deadline, progress in Patrick Soon-Shiong’s ‘cancer moonshot’ is hard to find

3 trends in biotech to watch in 2020

Sarepta sells international rights to Duchenne gene therapy to Roche

Ring Therapeutics is developing a new way to deliver gene therapy

The FTC moves to block DNA sequencer Illumina’s acquisition of PacBio, calling company a ‘monopolist’

Startup targeting DNA repeats in Huntington’s and other diseases debuts with $59 million

Purdue, maker of OxyContin, quietly splits ways with PhRMA as it pulls back from lobbying

Bankrupt uBiome preliminarily sells patents for 1% of the poop-testing startup’s original valuation

In tight Massachusetts job market, it’s relo for biotech and remote for tech hires

Bristol-Myers CMO on cell therapies: ‘This is the best time to be in drug development’

Vindicated. New J&J CAR-T myeloma data confirm strong efficacy, ease doubts raised by Chinese version

New data show Bluebird, Bristol CAR-T drug could be pioneering myeloma therapy. Competitors may be close behind

How difficult is a $1 billion health-tech fraud? A new indictment makes it sound easy

Global Blood secures FDA approval for new pill to treat sickle cell disease

Facing bottlenecks in manufacturing cell therapies, Boston leaders plan to build their own

With $9.7 billion acquisition, Novartis bets that heart drugs are coming back

Patient charity settles allegations it helped MS drug makers pay kickbacks

Roche buying Promedior for $390 million to develop drugs for fibrotic disease

An FDA panel backed Amarin’s fish oil drug. Here’s a detailed breakdown of the debate

Mass. governor — and one-time insurance executive — eyes a legacy-defining revamp of state’s health care

FDA documents point to a broadened approval for Amarin’s heart pill Vascepa

Sarepta Therapeutics CEO playing nice with FDA over rejection of Duchenne drug

Startup Arkuda targets rapidly advancing, rare form of dementia

If Trump were to place tariffs on Swiss drugs, U.S. patients are most likely to get hurt

A new Alzheimer’s therapy is approved in China, delivering a surprise for the field but also questions

Amgen acquires stake in BeiGene to expand cancer drug business to China

Novartis’ Zolgensma gene therapy study halted by FDA on animal safety concerns